Medications
PreclinicalSmall molecule
Medications is one of 46 small molecule programs targeting Psychosis. It is currently in Preclinical.
3
Indications
5
Total Trials
1
Active Trials
45
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
40 competitors in Psychosis
#DrugCompanyPhaseTrials
1Geodon
PfizerApproved
Abilify
OtsukaApproved
Cysteine Hydrochloride
NovartisApproved
Risperdal
WWim Janssens
Approved
Seroquel
EEngelhard Arzneimittel GmbH & Co.KG
Approved
Zyprexa
MMODAG GmbH
Approved
Vraylar
AbbVieApproved
Niacor
AbbVieApproved
Barhemsys
Tibotec Pharmaceuticals, IrelandApproved
Invega
WWim Janssens
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Dental Implant1 trial
Quality of Life1 trial
Benson Relaxation Technique Effectiveness on Pain and Quality of Life Post Reconstructive Mammoplasty
Not yet recruiting·—·N/A·NCT07032883·68 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Medications. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- YYale University